StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie epkinly (epcoritamab) — Worldwide net revenues ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues

QuarterlyAnnual
Latest, Q2 2026
103
Period ended Jun 30, 2026
Change on a year earlier
+47.1%
70 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEpkinly (epcoritamab) — Worldwide net revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026103+47.1%Form 10-Q (filed 2026-08-03) ↗
Q1 2026Mar 31, 202683+62.7%Form 10-Q (filed 2026-05-08) ↗
Q4 2025Dec 31, 202581+102.5%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 202569+60.5%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 202570+94.4%Form 10-Q (filed 2026-08-03) ↗
Q1 2025Mar 31, 202551+88.9%Form 10-Q (filed 2026-05-08) ↗
Q4 2024Dec 31, 202440+135.3%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 202443+207.1%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 202436–Form 10-Q (filed 2025-08-04) ↗
Q1 2024Mar 31, 202427–Form 10-Q (filed 2025-05-09) ↗
Q4 2023Dec 31, 202317–Form 10-K (filed 2026-02-20) ↗
Q3 2023Sep 30, 202314–Form 10-Q (filed 2024-11-04) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-05-03) ↗

Breakdown

What makes up epkinly (epcoritamab) — worldwide net revenues ($m)

Cite this data

StockData. (2026). AbbVie Epkinly (epcoritamab) — Worldwide net revenues ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/epkinly_ww

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.